<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Clin Biochem</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Clin Biochem</journal-id><journal-title-group><journal-title>Indian Journal of Clinical Biochemistry</journal-title></journal-title-group><issn pub-type="ppub">0970-1915</issn><issn pub-type="epub">0974-0422</issn><publisher><publisher-name>Springer India</publisher-name><publisher-loc>New Delhi</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7424135</article-id><article-id pub-id-type="publisher-id">919</article-id><article-id pub-id-type="doi">10.1007/s12291-020-00919-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>The Pathophysiology, Diagnosis and Treatment of Corona Virus Disease 2019 (COVID-19)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0908-5437</contrib-id><name><surname>Das</surname><given-names>Subir Kumar</given-names></name><address><email>drsubirkdas@yahoo.co.in</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.418546.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1799 577X</institution-id><institution>Department of Biochemistry, College of Medicine and JNM Hospital, </institution><institution>WBUHS, </institution></institution-wrap>Kalyani, Nadia, West Bengal 741235 India </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>8</month><year>2020</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2020</year></pub-date><volume>35</volume><issue>4</issue><fpage>385</fpage><lpage>396</lpage><history><date date-type="received"><day>2</day><month>6</month><year>2020</year></date><date date-type="accepted"><day>4</day><month>8</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; Association of Clinical Biochemists of India 2020</copyright-statement></permissions><abstract id="Abs1"><p id="Par1">Since the beginning of this century, beta coronaviruses (CoV) have caused three zoonotic outbreaks. However, little is currently known about the biology of the newly emerged SARS-CoV-2 in late 2019. There is a spectrum of clinical features from mild to severe life threatening disease with major complications like severe pneumonia, acute respiratory distress syndrome, acute cardiac injury and septic shock. The genome of SARS-CoV-2 encodes polyproteins, four structural proteins and six accessory proteins. SARS-CoV-2 tends to utilize Angiotensin-converting enzyme 2 (ACE2) of various mammals. The imbalance between ACE/Ang II/AT1R pathway and ACE2/Ang(1&#x02013;7)/Mas receptor pathway in the renin-angiotensin system leads to multi-system inflammation. The early symptoms of COVID-19 pneumonia are low to midgrade fever, dry cough and fatigue. Vigilant screening is important. The diagnosis of COVID-19 should be based on imaging findings along with epidemiological history and nucleic acid detection. Isolation and quarantine of suspected cases is recommended. Management is primarily supportive, with newer antiviral drugs/vaccines under investigation.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Angiotensin</kwd><kwd>Angiotensin converting enzyme</kwd><kwd>Chloroquine</kwd><kwd>Corona virus</kwd><kwd>COVID-19</kwd><kwd>Cytokine storm</kwd><kwd>RNA-dependent</kwd><kwd>RNA polymerase</kwd><kwd>Spike protein</kwd><kwd>SARS-CoV2</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Association of Clinical Biochemists of India 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Coronaviruses (CoVs) is accountable for mixture of ailments in human and animals that include respiratory, enteric, renal, and neurological diseases [<xref ref-type="bibr" rid="CR1">1</xref>]. These are categorized into four genera, for instance alpha-CoV, beta-CoV, gamma-CoV, and delta-CoV2. Seven coronaviruses (CoVs) of beta-CoVs have been isolated from human beings till date [<xref ref-type="bibr" rid="CR2">2</xref>]. There have already been three zoonotic outbreaks in this century. Severe acute respiratory syndrome coronavirus (SARS-CoV) with about 10% case fatality rate (CFR) was initially witnessed from China in 2002, while Middle East respiratory syndrome coronavirus (MERS-CoV) infection with about 34.4% CFR was originally detailed from Saudi Arabia in June 2012 [<xref ref-type="bibr" rid="CR2">2</xref>]. This third outbreak coronavirus disease 19 (COVID-19) is indisputably the most frightening compared to the previous epidemics, which has spread from a marketplace in Wuhan, China in December 2019 to more than 213 countries and territories, infecting more than 1.5 crore people with death toll more than 6 lakhs of the world within nine months. With nearly 4% CFR, we have never thought anything like this highly contagious and pathogenic COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since the Spanish flu [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par3">However, pathogenesis of SARS-CoV-2 is yet to decode and as result there is no appropriate management for COVID-19 patients. This article focuses on understanding the structure of the virus, pathogenesis for disease progression, diagnosis of the disease with pros and cons of different treatment strategies.</p><sec id="Sec2"><title>Structure</title><p id="Par4">SARS-CoV-2 is positive-sense, single-stranded RNA connected to a nucleoprotein surrounded by a matrix protein based capsid (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR4">4</xref>]. Among the RNA viruses, the human CoV has the biggest viral genome [27&#x02013;32 kilobase pairs (kb)] with 80&#x02013;160&#x000a0;nm in diameter [<xref ref-type="bibr" rid="CR2">2</xref>]. A classic CoV has no less than six open reading frames (ORFs) in its genome. All the structural and accessory proteins of CoVs are translated from it&#x02019;s single guide RNAs (sgRNAs) [<xref ref-type="bibr" rid="CR4">4</xref>]. Two big overlapping ORFs, ORF 1a and ORF 1b, reside in two-thirds of the genome at the 50-terminus, and a third of the genome at the 30-terminus encodes for four conventional structural proteins in the sequential arrangement of spike (S), envelope (E), membrane (M), and nucleocapsid (N) (50&#x02013;30) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a). The genome of SARS-CoV-2 encodes polyproteins pp1ab, four structural proteins and six accessory proteins (3a, 6, 7a, 7b, 8, and 10), which is comparable to the structure of SARSCoV and MERS-CoV (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b) [<xref ref-type="bibr" rid="CR2">2</xref>]. The viral ORFs are produced through purifying selection. The most restricted sequences corresponded to a few non-structural proteins (nsps) and membrane protein [<xref ref-type="bibr" rid="CR5">5</xref>] (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Schematic structure of virion of SARS-CoV, MERS-CoV, and 2019-nCoV (SARS-CoV2) and its major structural proteins</p></caption><graphic xlink:href="12291_2020_919_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Schematic diagram of genomic organization of SARS-CoV, MERS-CoV, and SARS-CoV.2. <bold>a</bold> The genomic regions or open-reading frames (ORFs) are compared. <bold>b</bold> Structural proteins, including spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins, as well as non-structural proteins translated from ORF 1a and ORF 1b and accessory (A) proteins are indicated for SARS-CoV, MERS-CoV and SARS-CoV2</p></caption><graphic xlink:href="12291_2020_919_Fig2_HTML" id="MO2"/></fig></p><p id="Par5">Different proteins of human CoVs play important roles for viral infection and/or pathogenesis (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR2">2</xref>]. Surface glycoprotein of the virus displayed five cytotoxic T lymphocyte (CTL) epitopes, three sequential B cell epitopes and five discontinuous B cell epitopes [<xref ref-type="bibr" rid="CR6">6</xref>]. B cell mediated humoral immune response causes the clearance of SARS-CoV-2, while T cells play a fundamental role in viral infections [<xref ref-type="bibr" rid="CR7">7</xref>]. The CTL epitopes attach to the major histocompatibility complex (MHC) Class I peptide-binding grooves with uninterrupted hydrogen bonds and salt bridge anchors, which is accountable for immune responses, leading to the development of subunit vaccines [<xref ref-type="bibr" rid="CR6">6</xref>].<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Functions of different parts of SARS-CoV2 proteins</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Protein</th><th align="left">Function</th></tr></thead><tbody><tr><td align="left">Non-structural proteins (nsps)</td><td align="left">Viral RNA replication and/or transcription</td></tr><tr><td align="left">accessory proteins</td><td align="left">interact with host cells that help the viruses to evade the immune system and enhances their virulence</td></tr><tr><td align="left">Membrane (M) and Envelop (E) proteins</td><td align="left">virus assembly and promote virulence</td></tr><tr><td align="left">Spike (S) protein</td><td align="left">mediates viral entry into host cells and thereby membrane fusion, facilitating viral infection</td></tr></tbody></table></table-wrap></p><p id="Par6">The S protein can be fragmented into two functional subunits, N-terminal S1 subunit and a C-terminal S2 subunit (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Every monomer of trimeric S protein is approximately 180&#x000a0;kDa, and is liable for attachment and membrane fusion. In the structure, N- and C- terminal parts of S1 fold acts as two autonomous domains: N-terminal domain (NTD) and C-terminal domain (CTD) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Based on the virus, either NTD or CTD can function as the receptor-binding domain (RBD) [<xref ref-type="bibr" rid="CR1">1</xref>]. In adiition, a polybasic (furin) fragmenting site at the junction of the S1 and S2 subunits in the Spike protein of the SARS-CoV-2 was reported, which is absent in the other SARS-like CoVs [<xref ref-type="bibr" rid="CR8">8</xref>]. Data suggests that SARS-CoV-2 is intimately shared with SARS-CoV structural proteins having only 12.8% of difference in S protein and has 83.9% similarity in minimal RBD [<xref ref-type="bibr" rid="CR9">9</xref>].<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Diagram of full-length SARS-CoV2 Spike (S) protein; S1 receptor binding subunit; S2 membrane fusion subunit; TM, transmembrane domain; HR-N, heptad repeat-N; HR-C, heptad repeat-C</p></caption><graphic xlink:href="12291_2020_919_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec3"><title>Genomic Analysis</title><p id="Par7">Using all accessible genomic information, the phylogenetic tree investigation has ascertained the high sequence similarity (&#x0003e;&#x02009;99%) between all the existing sequenced SARS-CoV-2 genomes, with the closest as Bat coronavirus (BCoV) sequence resembling 96.2% sequence identity [<xref ref-type="bibr" rid="CR10">10</xref>], while pangolin-CoV shares 85.98% identity [<xref ref-type="bibr" rid="CR11">11</xref>], authenticating the conception of a zoonotic origin of 2019-nCoV [<xref ref-type="bibr" rid="CR10">10</xref>]. Other studies including full genome sequencing of strains from China, Japan, USA, Finland and Korea showed more than 99.9% sequence homology [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Sequence homology of SARS-CoV-2 with SARS-CoV, and MERS-CoV was accounted 77.5% and 50%, respectively [<xref ref-type="bibr" rid="CR12">12</xref>]. One study on the sequences of SARS-CoV-2 from India illustrated high (~&#x02009;99.98%) identity with Wuhan seafood market pneumonia virus (accession number: NC 045512) [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par8">Analysing the 15 obtainable whole genome sequences of SARS-CoV-2, 12 whole genome sequences of SARS-CoV-2 and 12 extremely related whole genome sequences available in gene bank (five from the SARS-CoV, two from MERS-CoV, and five from bat SARS-like CoV) explained the mutation in spike glycoprotein and nucleocapsid protein [<xref ref-type="bibr" rid="CR15">15</xref>]. It has been suggested that C-to-U conversion mediated by C deamination played a significant role in the evolution of the SARS-CoV-2 [<xref ref-type="bibr" rid="CR16">16</xref>]. These outcomes implied that SARS-CoV-2 could have been evolving for a relatively long period in humans following the transfer from animals before spreading worldwide.</p><p id="Par9">One study identified 12 novel recurrent mutations in South American and African viral genomes, among which 3 were exclusively in South America, 4 in Africa and 5 were present in-patient isolates from both populations [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par10">Phylogenetic and alignment study of 591 novel coronaviruses of different clades from Group I to Group V identified several mutations and related amino acid changes. Detailed analysis on nucleotide substitution revealed 43 synonymous and 57 non-synonymous type substitutions in the coding region [<xref ref-type="bibr" rid="CR17">17</xref>]. The nonsynonymous substitutions resulting into 57 amino acid changes were reported to be distributed over different human CoV proteins with maximum on spike protein [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par11">Out of 3617 available complete genome sequences of SARS-CoV2 from across the world maintained in the National Center for Biotechnology Information (NCBI) database, the E protein possesses several non-synonymous mutations [<xref ref-type="bibr" rid="CR18">18</xref>]. In another study, analysis of 10 SARS-CoV2 sequences by genome alignment from the NCBI database, did not report difference in amino acid sequences within M and N proteins, while two amino acid variances in the S protein region were reported. Two possible &#x0201c;L&#x0201d; and &#x0201c;S&#x0201d; SNPs were found in ORF1ab and ORF8 regions [<xref ref-type="bibr" rid="CR19">19</xref>]. A third study, utilising genomes of twenty-nine 2019-nCoV and thirty &#x003b2;-coronavirus, it was found that E genes were extremely conserved (99.56%), while S genes had lowest identity (92.87%), suggesting that S gene was of a rapid evolutionary rate [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par12">Analysis of the spike protein sequences from all five identified isolates from the state of West Bengal (Eastern India), two mutations were reported at position 723 and 1124 in the S2 domain. This mutation decreases the flexibility of S2 domain. Another mutation at the downstream of the receptor binding domain (RBD) at position 614 in S1 domain was found similar with the sequence reported from Gujarat (a state of western India). These mutations may be responsible for the affinity or avidity of receptor binding [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par13">In another study, analysis of thirty-two genomes of Indian COVID 19 patients revealed that ORF3a gene possesses single and double point mutations. The phylogenetic analysis revealed that the parental origin of the ORF3a gene over the genomes of SARS-CoV2 and Pangolin-CoV is same [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par14">All these investigations reliably suggested that 2019-nCoV is most narrowly related to BatCoV RaTG13 and belongs to subgenus Sarbecovirus of Betacoronavirus, together with SARS CoV and Bat-SARS-like Cov [<xref ref-type="bibr" rid="CR22">22</xref>]. Evolutionary scrutiny using ORF1a/1b, S and N genes also implied that 2019-nCoV is probably a novel CoV, which is independently introduced to humans from animals [<xref ref-type="bibr" rid="CR23">23</xref>].</p></sec><sec id="Sec4"><title>Symptoms</title><p id="Par15">The incubation phase of COVID-19 is 3&#x02013;7&#x02009;days globally. Approximately 80% of infectious cases remain mild or asymptomatic, 15% are severe and 5% infectious cases turn to critical, who require ventilation [<xref ref-type="bibr" rid="CR24">24</xref>]. Three major courses of infection include mild disease with upper respiratory symptoms, non-severe pneumonia, and severe pneumonia complicated by acute respiratory distress syndrome (ARDS) and multi organ failure [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par16">Fever and cough are the foremost common symptoms, whereas dyspnea, fatigue, shortness of breath and chest distcomfort are observed in moderate to severe cases [<xref ref-type="bibr" rid="CR26">26</xref>]. Olfactory and taste disorders also are reported in COVID-19 patients, who may not have nasal indications [<xref ref-type="bibr" rid="CR27">27</xref>]. Patients may further suffer from extra-pulmonary manifestations, including those influencing the liver and GI tract, with indications like diarrhoea, vomiting and abdominal pain [<xref ref-type="bibr" rid="CR28">28</xref>].</p></sec><sec id="Sec5"><title>Transmission</title><p id="Par17">Infection by droplets contaminating hands and surfaces are the foremost means of dispersal of the virus [<xref ref-type="bibr" rid="CR29">29</xref>]. GI tract is also a plausible spreading pathway and target organ of SARS-CoV-2 [<xref ref-type="bibr" rid="CR30">30</xref>]. One study demonstrated the presence of SARS-CoV-2 RNA in feces of COVID-19 patients, and suggested the chance of SARS-CoV-2 transmission through the fecal&#x02013;oral route [<xref ref-type="bibr" rid="CR28">28</xref>]. SARS-CoV-2 may also be noticed within the tears and conjunctival secretions in another study [<xref ref-type="bibr" rid="CR31">31</xref>]. Airborne diffusion of SARS-CoV-2 may also take place if patient respiratory activity or medical processes generate respiratory aerosols [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec id="Sec6"><title>Pathogenesis</title><p id="Par18">SARS-CoV-2 primarily targets the lungs, the vasculatures, and the immune system [<xref ref-type="bibr" rid="CR33">33</xref>]. The initial step of the viral multiplication is the binding to the surface of respiratory cells mediated by the spike (S) viral protein [<xref ref-type="bibr" rid="CR34">34</xref>]. It had been speculated that SARS-CoV-2 likely utilize angiotensin- converting enzyme 2 (ACE2, EC 3.4.17.23) of various mammals, except murines and a few birds, such as pigeon [<xref ref-type="bibr" rid="CR35">35</xref>]. The affinity of SARS-CoV-2 for ACE2 is 10&#x02013;20-higher than that of SARS- CoV [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p id="Par19">ACE2 is a metalloproteinase and shares about 60% homology with the carboxypeptidase angiotensin- converting enzyme (ACE, EC 3.4.15.1). ACE2, which is made up of 805 amino acids, is type I transmembrane glycoprotein having a single extracellular catalytic domain [<xref ref-type="bibr" rid="CR37">37</xref>]. Its expression is reported in the lungs, cardiovascular system, gut, kidneys, CNS and adipose tissue [<xref ref-type="bibr" rid="CR38">38</xref>]. It is the key active peptide of the renin-angiotensin system (RAS) or renin&#x02013;angiotensin&#x02013;aldosterone system (RAAS) [<xref ref-type="bibr" rid="CR38">38</xref>].</p><p id="Par20">Angiotensin II (Ang II) is the major effector of the RAAS that advances hypertension partly by decreasing baroreceptor sensitivity to maintain heart rate, and increasing vasoconstriction, sodium retention, oxidative stress, inflammation and fibrosis. Evidence from various studies favors a crucial function of ACE2 to efficiently degrade Ang II to Ang-(1-7), which antagonizes the effects of Ang II (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>) [<xref ref-type="bibr" rid="CR38">38</xref>]. Ang-(1&#x02013;7) acts on the Mas receptor that modestly reduces blood pressure through vasodilation, promoting excretion of sodium and water by the kidney, and also attenuate inflammation through the nitric oxide production (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>) [<xref ref-type="bibr" rid="CR36">36</xref>]. On the contrary, ACE converts Ang I into Ang II, which acts at the type 1 angiotensin receptor (AT1R) and increase blood pressure by inducing vasoconstriction, increasing kidney reabsorption of sodium and water by the kidney, and generating oxidative stress to promote inflammation and fibrosis (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>) [<xref ref-type="bibr" rid="CR36">36</xref>].<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Functional scheme of the renin-angiotensin system. The protease renin converts the precursor angiotensinogen to Angiotensin I (Ang I) and subsequently converted to Ang II by dipeptidyl carboxypeptidase angiotensin converting enzyme (ACE). Ang II binds to the AT1 receptor (AT1R) to stimulate inflammation, fibrosis, oxidative stress and an increase in blood pressure. Ang II are converted to Ang-(1-7) via endopeptidases (NEP) and the monocarboxypeptidase ACE2, respectively. Ang-(1-7) binds to the Mas-R to exert anti-inflammatory and anti-fibrotic actions, stimulate the release of nitric oxide and reduce blood pressure. SARS-CoV-2 binds to ACE2 to stimulate internalization of both the virus and peptidase causing deleterious effects. Angiotensin-converting enzyme inhibitors (ACEIs)/Angiotensin receptor blockers (ARBs) regulate the metabolic pathway</p></caption><graphic xlink:href="12291_2020_919_Fig4_HTML" id="MO4"/></fig></p><p id="Par21">The S1 domain of the SARS-CoV attaches to its cellular receptor ACE2 on the host cells [<xref ref-type="bibr" rid="CR39">39</xref>]. Binding of the SARS- CoV-2 spike protein to ACE2, followed by a conformational change in the S-glycoprotein permitting proteolysis of ACE2 by transmembrane serine protease 2 (TMPRSS2) to generate the S1 and S2 subunits is a critical step for S2-induced membrane fusion and virus internalization by endocytosis in the pulmonary epithelium. The entry of the virus into cells further facilitates virus multiplication and cell- to- cell transmission [<xref ref-type="bibr" rid="CR39">39</xref>], and is thought to suppress expression of ACE2. This suppression of ACE2 causes decrease in tissue level and reduces Ang-(1&#x02013;7) formation, and correspondingly increase in Ang II levels. ACE further converts Ang-(1&#x02013;7) to less biologically active peptides. This process can drive an Ang II&#x02013;AT1R- mediated inflammatory response in the lungs and prospectively stimulate parenchymal injury [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p id="Par22">The pathogenesis involves two interconnected processes: lung inflammation and immune deficiency, both of which are related to an improper immunologic response and over-production of proinflammatory cytokines [<xref ref-type="bibr" rid="CR33">33</xref>], Additionally, altered redox balance in infected cells through alteration of NAD<sup>+</sup> biosynthesis, poly (ADP-ribose) polymerase (PARP) function along with changeing proteasome and mitochondrial function further exacerbate inflammation and lipid peroxidation resulting in cell damage [<xref ref-type="bibr" rid="CR40">40</xref>]. Furthermore, SARS-CoV-2 induced activation of apoptosis and p53 signaling pathway in lymphocytes causes lymphopenia in such patients [<xref ref-type="bibr" rid="CR41">41</xref>].</p><p id="Par23">SARS-CoV-2 demonstrates neurotropic behaviour and may also cause neurological diseases. It is reported that CoV are often found in the brain or cerebrospinal fluid [<xref ref-type="bibr" rid="CR42">42</xref>]. Another feature of severe COVID-19 is coagulopathy, which is determined by elevated plasmin(ogen) in such patients. Plasmin and other proteases, may cleave furin site in the S protein of SARS-CoV-2 extracellularly, which increases its infectivity and virulence, and is related to hyperfibrinolysis [<xref ref-type="bibr" rid="CR43">43</xref>].</p></sec><sec id="Sec7"><title>Factors Associated with Pathogenesis- age, Gender and Co-morbidities</title><p id="Par24">Studies have shown that SARS-CoV-2 causes worse outcomes and a higher mortality rate in older people (more than 60 years of age) and those with comorbidities such as hypertension, cardiovascular disease, diabetes mellitus, chronic respiratory disease, and chronic kidney disease [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. The COVID-19 virus appears to cause mild infections in children. Though the reasons for this tolerance is unknown, some researchers suggested that non-susceptibility of children to coronavirus may be due to separate ACE activity [<xref ref-type="bibr" rid="CR45">45</xref>], and active innate immune response caused by trained immunity (secondary to live-vaccines and frequent viral infections). Adult patients are believed to have suppressed adaptive immunity and dysfunctional innate immune response [<xref ref-type="bibr" rid="CR46">46</xref>].</p><p id="Par25">It is believed that women, compared to men, are less vulnerable to viral diseases due to dissimilar innate immunity, steroid hormones and factors related to sex chromosomes. The immune regulatory genes encoded by X chromosome in female category causes lower viral load, and less inflammation than in man, while CD4+ T cells are higher with better immune response. Higher TLR7 in women and its biallelic expression is responsible for better immune responses and enhances the fighting to viral infections in comparison to men [<xref ref-type="bibr" rid="CR47">47</xref>].</p><p id="Par26">Myocardial injury is one of the important pathogenic features of COVID-19, possibly due to direct damage to the cardiomyocytes, systemic inflammation, myocardial interstitial fibrosis, interferon mediated immune response, exaggerated cytokine response by Type 1 and Type 2 helper T cells, in addition to coronary plaque destabilization, and hypoxia [<xref ref-type="bibr" rid="CR48">48</xref>].</p><p id="Par27">COVID-19 may augment complications in individuals with diabetes through an imbalance in ACE2 activation pathways leading to an inflammatory response and &#x003b2;-cell dysfunction in the pancreas, which may deteriorate COVID-19 complications including vasculopathy, coagulopathy and psychological stress [<xref ref-type="bibr" rid="CR49">49</xref>]. The chronic low grade inflammation in diabetes and obesity can also lead to an enhanced &#x02018;cytokine storm&#x02019; in COVID-19 patients [<xref ref-type="bibr" rid="CR50">50</xref>].</p><p id="Par28">Respiratory epithelium cells of smokers and patients with COPD express higher ACE2 receptor. Nicotine binds and enhances nicotinic acetylcholine receptors (nAChR), specifically the &#x003b1;7subtype (&#x003b1;7-nAChR) in lungs and various other tissues, particularly in central nervous system. Increased expression of ACE2 receptors is mediated by stimulation of &#x003b1;7-nAChR, and facilitates the SARS-CoV-2 entry of into the respiratory epithelium [<xref ref-type="bibr" rid="CR51">51</xref>]. ACE2 expression on endothelial cells is associated with virus mediated endothelitis and precipitate vascular dysfunction manifesting as acute respiratory distress syndrome (ARDS) [<xref ref-type="bibr" rid="CR50">50</xref>].</p><p id="Par29">One meta-analysis comprising 1558 patients with COVID-19 from 6 studies revealed no association between the increased risk of COVID-19 with liver disease, malignancy, or renal diseases [<xref ref-type="bibr" rid="CR52">52</xref>].</p></sec><sec id="Sec8"><title>Diagnosis</title><p id="Par30">Viral serological test is an efficient investigative means to determine the prevalence for SARS-CoV-2 infection among the population [<xref ref-type="bibr" rid="CR53">53</xref>]. COVID-19 infection stimulates IgG antibodies against N protein that can be noticed in serum as early as day 4 after the onset of disease, and in most patients seroconversion take place by day 14 [<xref ref-type="bibr" rid="CR24">24</xref>]. IgG illustrated higher positive rate and titer variance than that of IgM in COVID-19 [<xref ref-type="bibr" rid="CR53">53</xref>]. Detection of IgM and IgG against SARS-CoV-2 is a fast and easy monitoring method [<xref ref-type="bibr" rid="CR54">54</xref>]. Combined examination of the IgM-IgG proved better efficacy and sensitivity compared to a single antibody [<xref ref-type="bibr" rid="CR55">55</xref>].</p><p id="Par31">A decreased lymphocyte count and an increased high-sensitivity C-reactive protein (hs-CRP) level are the most common laboratory findings [<xref ref-type="bibr" rid="CR56">56</xref>]. As the infection advances, white blood cell count (WBC), neutrophil count, platelet count, red blood cell distribution width-coefficient of variation (RDW-CV), and RDW-standard deviation (RDW-SD) parameters elevates with severity of the diseases; while, lymphocyte count, eosinophil count, red blood cell count (RBC), hemoglobin, and hematocrit parameters decreases. The combined neutrophil-to-lymphocyte ratio and RDW-SD parameter is the best hematology index [<xref ref-type="bibr" rid="CR57">57</xref>].</p><p id="Par32">The assenting diagnosis of COVID-19 is dependent on the viral isolation by polymerase chain reaction (PCR) from sputum, or nasal swab, or throat swab for the categories of those with symptoms or potentially exposed [<xref ref-type="bibr" rid="CR58">58</xref>]. The real-time-reverse transcription (RT)-PCR detection of viral nucleic acid test (NAT) is considered as sensitive, specific and able to process large batches of samples [<xref ref-type="bibr" rid="CR59">59</xref>]. The RT-PCR results generally become positive after 2&#x02013;8&#x000a0;days [<xref ref-type="bibr" rid="CR60">60</xref>]. However, the commonly used RT-PCR method shows false-negative in some cases, such as mutations of the SARS-CoV-2 genome, variable viral load kinetics or laboratory errors [<xref ref-type="bibr" rid="CR61">61</xref>]. It may lack sensitivity, particularly in the advanced phase of infection, and depends closely on the samples&#x02019; quality [<xref ref-type="bibr" rid="CR62">62</xref>]. As turnaround time of RT-PCR is long, molecular point of care tests (POCT) should be considered in situations where quick results are critical [<xref ref-type="bibr" rid="CR59">59</xref>].</p><p id="Par33">This rapid PCR by cartridge system (CBNAAT: cartridge-based nucleic acid amplification test or GeneXpert polymerase chain reaction test) reduces response times [<xref ref-type="bibr" rid="CR62">62</xref>], demonstrated equal performance compared to routine in-house RT-PCRs [<xref ref-type="bibr" rid="CR59">59</xref>], but is not suitable for laboratories with high throughput of requests [<xref ref-type="bibr" rid="CR62">62</xref>].</p><p id="Par34">Computed tomography (CT) can be considered as an essential supplemental investigative tool for the detection of COVID-19 pneumonia in this pandemic context. In severe cases, CT plays an important role in identifying viral lung infection, examining the nature and extent of pulmonary lesions, and scrutinizing the disease severity [<xref ref-type="bibr" rid="CR63">63</xref>]. Known features of COVID-19 on initial CT consist of bilateral multilobar with an usual of three lung segments, ground-glass opacification (GGO) with a peripheral or posterior distribution, principally in the lower lobes and some times inside the right middle lobe. Consolidative opacities superimposed on GGO may be reported in a few elderly population. Other uncommon findings include septal thickening, bronchiectasis, pleural thickening, and subpleural involvement, which are rarely reported in the later stages of the disease [<xref ref-type="bibr" rid="CR64">64</xref>]. The imaging pattern readily change over a short period of time [<xref ref-type="bibr" rid="CR65">65</xref>].</p><p id="Par35">However, CT decontamination is essential after scanning COVID-19 patients, which may disarray radiological service accessibility and advocates that chest radiography may lessen the risk of cross-infection [<xref ref-type="bibr" rid="CR66">66</xref>]. In COVID-19, chest X-ray (CXR) shows patchy or diffuse reticular-nodular opacities and consolidation, with basal, peripheral and bilateral predominance [<xref ref-type="bibr" rid="CR67">67</xref>]. The consideration of CXR for early detection may contribute an important role in the regions around the world with limited access to RT-PCR COVID testing [<xref ref-type="bibr" rid="CR66">66</xref>].</p><p id="Par36">Increased cytokine levels (IL-6, IL-10 and TNF&#x003b1;), lymphopenia (in CD4+ and CD8+ T cells), and decreased IFN-&#x003b3; expression in CD4+ T cells are linked with severe COVID-19, illustrating the &#x0201c;cytokine storm&#x0201d; [<xref ref-type="bibr" rid="CR68">68</xref>].</p><p id="Par37">Some patients are detectd with definite disseminated intravascular coagulation (DIC) [<xref ref-type="bibr" rid="CR69">69</xref>]. This DIC is primarily pro-thrombotic with high venous thromboembolism rate, increased D-dimer and fibrinogen levels, reduced anti-thrombin levels, pulmonary congestion with microvascular thrombosis and occlusion on pathology besides high rates of central line thrombosis and vascular occlusive events (e.g. ischemic limbs, strokes, etc.) [<xref ref-type="bibr" rid="CR69">69</xref>].</p><p id="Par38">There is no study exclusively in asymptomatic participants. Combination of clinical presentation, imaging features and laboratory findings could help early diagnosis of COVID-19 pneumonia.</p></sec><sec id="Sec9"><title>Preventive Measures</title><p id="Par39">Infection can spead only in the existence of contact. Nosocomial spread is usually controlled through preliminary infection control measures, including wearing of face masks, respiratory etiquette, hand and environmental hygiene [<xref ref-type="bibr" rid="CR70">70</xref>]. Personal protective equipment (PPE) is a vital element; but it is just one component of a shielding system from COVID-19 infection [<xref ref-type="bibr" rid="CR32">32</xref>]. Quarantine or physical segregation is vital to confirm effectiveness, including short- to medium-term lockdowns, voluntary home curfew, curb on the gathering of people, cessation of social and public events and closure of mass transit systems [<xref ref-type="bibr" rid="CR71">71</xref>].</p></sec><sec id="Sec10"><title>Treatment</title><p id="Par40">As extracorporeal membrane oxygenation (ECMO) is considered as an efficient remedy in the treatment of severe COVID-19 [<xref ref-type="bibr" rid="CR72">72</xref>].</p><p id="Par41">No valdated medicine is available till date against COVID-19. Some drugs that are indicated for other afflictions are being tested, although without unambiguous evidence.&#x000a0;Lipophilic antibiotics tetracyclines (e.g. tetracycline, doxycycline, and minocycline) can chelate zinc (Zn) compounds on matrix metalloproteinases (MMPs). Coronaviruses are believed to depend on host MMPs for survival, cell infiltration, cell to cell adhesion, and replication; many of those have Zn as a part of their MMP complex. It is possible that the Zn-chelating characteristic of tetracyclines may be responsible to inhibit SARS-CoV-2 infection in humans, and controlling their capacity to multiply within the host [<xref ref-type="bibr" rid="CR73">73</xref>]. Ivermectin, an FDA-approved anti-parasitic drug that was previously shown as broad-spectrum anti-viral activity in vitro, was reported as an inhibitor of the causative virus (SARS-CoV-2) in Vero-hSLAM cells [<xref ref-type="bibr" rid="CR74">74</xref>].</p><p id="Par42">The spike (S) protein on the viral envelope, is believed as a major intention of vaccine development for the prevention of coronavirus infection. The choices to block viral ingress include the employment of natural neutralizing antibodies from convalescent plasma (discussed elsewhere within the manuscript) and engineered antibodies. Engineered antibodies or neutralizing fragments are often utilised in various formats. The antibody/Fc-receptor complex imitates viral receptor to intervene viral entry. Antibody-dependent enhancement (ADE) of viral entrance has been observed for several viruses. In such cases, antibodies mark one serotype of viruses and subneutralize another, causing to ADE of the second virus. A unique mechanism for the ADE is that a neutralizing antibody attaches to the S protein of coronaviruses like a viral receptor, triggers a conformational change of the spike, and mediates viral entry into IgG Fc receptor-conveying cells through canonical viral-receptor-dependent pathways [<xref ref-type="bibr" rid="CR75">75</xref>].</p><p id="Par43">Angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs) might possibly alleviate the RAS-induced lung injury, and restrict heart and renal damage. It was reported that ACEIs and/or ARBs increases the ACE2 expression, and also inhibit angiotensin-converting enzyme 1 (ACE1) or stops angiotensin II type 1 receptor (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Considering that ACE2 expression might be associated with the vulnerability to SARS-CoV-2, intake of ACEIs and/or ARBs might predispose patients to the infection of SARS-CoV-2 [<xref ref-type="bibr" rid="CR76">76</xref>]. However, due to the functional complexity of the RAAS and the lack of strong information on the activities of ACE2 expression in various tissues following the use of ACE inhibitors or angiotensin receptor blockers, it is difficult to speculate on the relevance of those ACE modulators [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>].</p><p id="Par44">Viral S-glycoprotein, TMPRSS2 and ACE-2 inhibition are important objectives of therapy and probably vaccine development [<xref ref-type="bibr" rid="CR39">39</xref>]. Subunit vaccines are commenced depending on the full-length S protein, receptor-binding domain (RBD), non-RBD S protein fragments, and non-S structural proteins [<xref ref-type="bibr" rid="CR2">2</xref>]. Using structure-based drug screening to detect SARS-CoV-2 protease blockers, macrolides (MAC) were believed to be effective for COVID-19 [<xref ref-type="bibr" rid="CR78">78</xref>].</p><p id="Par45">E proteins of SARS-CoV2 form ion channels. Result revealed that &#x003b1;-helix and loops present in this protein is associated with the random movement under optimal condition, which successively alter ion channel activity; and thereby developing the disease. Inhibition of those ion channels after binding with three phytochemicals, such as, belachinal, macaflavanone E, and vibsanol B, reduces the random motion of the human &#x0201c;SARS-CoV-2 E&#x0201d; protein, inhibit its function and controlling the disease [<xref ref-type="bibr" rid="CR79">79</xref>].</p><p id="Par46">The main protease (Mpro) of SARS CoV-2 is an important component of this viral replication. Three polyphenols (epigallocatechin gallate, epicatechingallate and gallocatechin-3-gallate) of green tea [<xref ref-type="bibr" rid="CR80">80</xref>] and compounds from <italic>Curcuma longa</italic> L. (Zingiberaceae family) [<xref ref-type="bibr" rid="CR81">81</xref>] interact strongly with one or both catalytic residues (His41 and Cys145) of Mpro, and are considered as potential inhibitors against SARS CoV-2 Mpro. Famotidine, a class A G protein-coupled receptor antagonist used for the treatment of gastroesophageal reflux, is reported to interact within the catalytic site of the three proteases associated with SARS-CoV2 replication [<xref ref-type="bibr" rid="CR82">82</xref>].</p><p id="Par47">There has been growing interest in the use of anti-malaria and anti-amebiasis drugs chloroquine (CQ, N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine) and hydroxychloroquine (HCQ), as potential treatments for COVID-19. Chloroquine inhibits quinone reductase 2, which is involved in the biosynthesis of sialic acids [<xref ref-type="bibr" rid="CR83">83</xref>]. CQ (or it&#x02019;s active derivative HCQ) inhbits attachment of the viral spike to the gangliosides [<xref ref-type="bibr" rid="CR34">34</xref>]. Further study suggested that both CQ and HCQ stall the movement of SARS-CoV-2 from endosomes to endolysosomes, which seems to be critical to discharge the viral genome [<xref ref-type="bibr" rid="CR84">84</xref>]. HCQ probably reduce the progression of COVID-19 severity, by hindering the &#x02018;cytokine storm&#x02019; through controlling the T lymphocyte activation [<xref ref-type="bibr" rid="CR85">85</xref>]. Azithromycin together with HCQ was reported considerably more efficient for virus elimination [<xref ref-type="bibr" rid="CR86">86</xref>]. However, there is inadequate proof to establish the safety and effectiveness of CQ/HCQ to treat COVID-19.</p><p id="Par48">A few broad-spectrum antiviral drugs were tested against COVID-19 in clinical trials. RNA-dependent RNA polymerase (RdRp) is an essential protease that mediates the replication of RNA from RNA template for coronaviruses and is an important therapeutic target. Some clinical assessments against viral RdRp inhibitors had been conducted. Favipiravir, a purine nucleic acid analogue and effective RdRp inhibitor, which is endorsed against influenza, is additionally being considered in different clinical trials [<xref ref-type="bibr" rid="CR87">87</xref>]. Remdesivir, an analogue of adenosine with broad-spectrum antiviral agent has shown a high capacity to block infection and viral replication in vitro and in animals with attainable concentrations in human plasma against SARS-CoV and MERS-CoV. It seems that remdesivir may be one amongst the few antiviral drugs with proven efficacy against SARS-CoV2 [<xref ref-type="bibr" rid="CR88">88</xref>] possibly by delayed RNA chain termination [<xref ref-type="bibr" rid="CR89">89</xref>].</p><p id="Par49">Recently, the mixture of three drugs, lopinavir, oseltamivir and ritonavir has been proposed to mitigate the virulence to a good extent in COVID-19 affected patients. Hence, these drugs are often explored further for drug repurposing against the successful inhibition of COVID-19 [<xref ref-type="bibr" rid="CR90">90</xref>]. A randomized controlled experiment of lopinavir/ritonavir showed no visible clinical or virologic benefit, and drug&#x02013;drug interactions and consequences further limit its utility [<xref ref-type="bibr" rid="CR91">91</xref>]. Oseltamivir demonstrated limited activity against SARS-CoV-2 [<xref ref-type="bibr" rid="CR91">91</xref>].</p><p id="Par50">Prevention of the cytokine storm may be one of the solution to save the patients with severe COVID-19 pneumonia. Limited pre-clinical data suggested that systemic mesenchymal stem cells (MSCs) administration could cure or significantly improved the functional outcomes in seven SARS-CoV2 patients without any adverse effect [<xref ref-type="bibr" rid="CR92">92</xref>]. Addition of anticytokinic biological agents, like anti-IL-1 (anakinra) [<xref ref-type="bibr" rid="CR93">93</xref>] or anti-IL-6 (tocilizumab (TCZ)) [<xref ref-type="bibr" rid="CR94">94</xref>] are also recommended.</p><p id="Par51">Anti-complement C5 therapy with eculizumab is reported to be a potential key player in treatment of severe cases of COVID-19 [<xref ref-type="bibr" rid="CR95">95</xref>]. Some studies reported that the use of corticosteroids might speed up improvement from COVID-19 [<xref ref-type="bibr" rid="CR96">96</xref>]. However, it is also reported that non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids may worsen conditions in SARS-CoV2 patients [<xref ref-type="bibr" rid="CR97">97</xref>]. Therefore, use of corticosteroids or Janus kinase (JAK) blockers need to be reconsidered in cases with hyperinflammation [<xref ref-type="bibr" rid="CR98">98</xref>]. One study indicated that Lianhuaqingwen, a conventional Chinese medicine formula significantly inhibited SARS-CoV-2 replication in Vero E6 cells and markedly reduced pro-inflammatory cytokines [<xref ref-type="bibr" rid="CR99">99</xref>].</p><p id="Par52">Memantine, an antagonist of &#x003b1;7-nAChR and NMDA receptors may lessen ACE2 receptors expression and reduce oxidative stress and inflammation [<xref ref-type="bibr" rid="CR51">51</xref>]. Early treatment with anti-oxidants such as N-acetyl cysteine during COVID-19 can be a way to control the excessive inflammation and cell damage [<xref ref-type="bibr" rid="CR40">40</xref>]. Various randomized controlled trials, pilot studies, case reports and in vitro and in vivo studies confirmed that <italic>Nigella sativa</italic> (black cumin seeds) that showed antiviral, antioxidant, anti-inflammatory, immunomodulatory, bronchodilatory, antihistaminic, antitussive activities, could be considered as an adjuvant therapy along with repurposed conventional drugs for management of COVID-19 patients [<xref ref-type="bibr" rid="CR100">100</xref>]. It further renders the importance of homocysteine-dependent trans-sulfuration pathway in COVID-19 infection. Hence, Vitamin B6, folic acid, and Vitamin B12 should also be included in the treatment regimen for SARS CoV-2 infections [<xref ref-type="bibr" rid="CR101">101</xref>].</p><p id="Par53">Passive antibody administration through transfusion of immune (i.e. &#x0201c;convalescent&#x0201d;) plasma are often recommended as the sole short-term strategy to confer immediate immunity to susceptible ones. This approach has been used as post-exposure prophylaxis and/or treatment of contagious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, MERS etc.) [<xref ref-type="bibr" rid="CR102">102</xref>]. Though limited data suggested significant improvement [<xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR104">104</xref>], however, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections and transfusion. Data from rigorously controlled clinical trials of convalescent plasma also are few [<xref ref-type="bibr" rid="CR102">102</xref>].</p><p id="Par54">There is proof that fibrinolytic therapy in acute lung injury and ARDS progresss to survival [<xref ref-type="bibr" rid="CR69">69</xref>]. Anticoagulant therapy chiefly with low molecular weight heparin seems to improve prognosis in severe COVID-19 patients suffering from hypercoagulation status or with increased D-dimer [<xref ref-type="bibr" rid="CR105">105</xref>].</p></sec><sec id="Sec11"><title>Challenges</title><p id="Par55">Considering the characteristic high mutation rates of RNA viruses, more mutations may emerge within the viral genome [<xref ref-type="bibr" rid="CR106">106</xref>]. Fortunately, coronaviruses likely have lower mutation rates in comparison to the other RNA viruses because of an intrinsic capacity for a few proof-reading activity due to 30-to-50 exoribonuclease. Lower mutation rates are partly balanced by high virus replication rate within hosts [<xref ref-type="bibr" rid="CR107">107</xref>].</p></sec></sec><sec id="Sec12"><title>Conclusion</title><p id="Par56">Given the high infection rate of this virus between humans and its pandemics, it is essential to understand the structure and basis of its pathogenicity for the advancement to the special treatment or the prevention. Due to the greater resemblance of the virus to its families, attempts have been made to expolore the medicines and vaccines for COVID-19. Identification of the specific molecular details of the virus is helpful in achieving treatment goals. It is also important to monitor any changes in phenotype as the virus spreads.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Compliance with Ethical Standards</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par57">None.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Mi</surname><given-names>D</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><etal/></person-group><article-title>Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>1620</fpage><?supplied-pmid 32221306?><pub-id pub-id-type="pmid">32221306</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>L</given-names></name></person-group><article-title>Subunit vaccines against emerging pathogenic human coronaviruses</article-title><source>Front Microbiol</source><year>2020</year><volume>11</volume><fpage>298</fpage><?supplied-pmid 32265848?><pub-id pub-id-type="pmid">32265848</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lodise</surname><given-names>TP</given-names></name><name><surname>Rybak</surname><given-names>MJ</given-names></name></person-group><article-title>COVID-19: important therapy considerations and approaches in this hour of need</article-title><source>Pharmacotherapy</source><year>2020</year><volume>40</volume><issue>5</issue><fpage>379</fpage><lpage>381</lpage><?supplied-pmid 32267556?><pub-id pub-id-type="pmid">32267556</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mousavizadeh</surname><given-names>L</given-names></name><name><surname>Ghasemi</surname><given-names>S</given-names></name></person-group><article-title>Genotype and phenotype of COVID-19: their roles in pathogenesis</article-title><source>J Microbiol Immunol Infect</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jmii.2020.03.022</pub-id><?supplied-pmid 32265180?><pub-id pub-id-type="pmid">32265180</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cagliani</surname><given-names>R</given-names></name><name><surname>Forni</surname><given-names>D</given-names></name><name><surname>Clerici</surname><given-names>M</given-names></name><name><surname>Sironi</surname><given-names>M</given-names></name></person-group><article-title>Computational inference of selection underlying the evolution of the novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2</article-title><source>J Virol</source><year>2020</year><volume>94</volume><issue>12</issue><fpage>e00411</fpage><lpage>e00420</lpage><?supplied-pmid 32238584?><pub-id pub-id-type="pmid">32238584</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baruah</surname><given-names>V</given-names></name><name><surname>Bose</surname><given-names>S</given-names></name></person-group><article-title>Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><issue>5</issue><fpage>495</fpage><lpage>500</lpage><?supplied-pmid 32022276?><pub-id pub-id-type="pmid">32022276</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noorimotlagh</surname><given-names>Z</given-names></name><name><surname>Karami</surname><given-names>C</given-names></name><name><surname>Mirzaee</surname><given-names>SA</given-names></name><name><surname>Kaffashian</surname><given-names>M</given-names></name><name><surname>Mami</surname><given-names>S</given-names></name><name><surname>Azizi</surname><given-names>M</given-names></name></person-group><article-title>Immune and bioinformatics identification of T cell and B cell epitopes in the protein structure of SARS-CoV-2: a systematic review</article-title><source>Int Immunopharmacol</source><year>2020</year><volume>86</volume><fpage>106738</fpage><?supplied-pmid 32683296?><pub-id pub-id-type="pmid">32683296</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coutard</surname><given-names>B</given-names></name><name><surname>Valle</surname><given-names>C</given-names></name><name><surname>de Lamballerie</surname><given-names>X</given-names></name><name><surname>Canard</surname><given-names>B</given-names></name><name><surname>Seidah</surname><given-names>NG</given-names></name><name><surname>Decroly</surname><given-names>E</given-names></name></person-group><article-title>The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade</article-title><source>Antivir Res</source><year>2020</year><volume>176</volume><fpage>104742</fpage><?supplied-pmid 32057769?><pub-id pub-id-type="pmid">32057769</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Maurya</surname><given-names>VK</given-names></name><name><surname>Prasad</surname><given-names>AK</given-names></name><name><surname>Bhatt</surname><given-names>MLB</given-names></name><name><surname>Saxena</surname><given-names>SK</given-names></name></person-group><article-title>Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)</article-title><source>Virus Dis</source><year>2020</year><volume>31</volume><issue>1</issue><fpage>13</fpage><lpage>21</lpage></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceraolo</surname><given-names>C</given-names></name><name><surname>Giorgi</surname><given-names>FM</given-names></name></person-group><article-title>Genomic variance of the 2019-nCoV coronavirus</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><issue>5</issue><fpage>522</fpage><lpage>528</lpage><?supplied-pmid 32027036?><pub-id pub-id-type="pmid">32027036</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chitranshi</surname><given-names>N</given-names></name><name><surname>Gupta</surname><given-names>VK</given-names></name><name><surname>Rajput</surname><given-names>R</given-names></name><name><surname>Godinez</surname><given-names>A</given-names></name><name><surname>Pushpitha</surname><given-names>K</given-names></name><name><surname>Shen</surname><given-names>T</given-names></name><etal/></person-group><article-title>Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CL(pro) targeting repurposed drug candidates</article-title><source>J Transl Med</source><year>2020</year><volume>18</volume><issue>1</issue><fpage>278</fpage><?supplied-pmid 32646487?><pub-id pub-id-type="pmid">32646487</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JM</given-names></name><name><surname>Chung</surname><given-names>YS</given-names></name><name><surname>Jo</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>NJ</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Woo</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Identification of coronavirus isolated from a patient in Korea with COVID-19</article-title><source>Osong Public Health Res Perspect</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>3</fpage><lpage>7</lpage><?supplied-pmid 32149036?><pub-id pub-id-type="pmid">32149036</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>XC</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>XF</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Genomic analysis of a 2019-nCoV strain in the first COVID-19 patient found in Hangzhou, Zhejiang, China</article-title><source>Zhonghua Yu Fang Yi Xue Za Zhi</source><year>2020</year><volume>54</volume><issue>5</issue><fpage>486</fpage><lpage>490</lpage><?supplied-pmid 32171191?><pub-id pub-id-type="pmid">32171191</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>PD</given-names></name><name><surname>Potdar</surname><given-names>VA</given-names></name><name><surname>Choudhary</surname><given-names>ML</given-names></name><name><surname>Nyayanit</surname><given-names>DA</given-names></name><name><surname>Agrawal</surname><given-names>M</given-names></name><name><surname>Jadhav</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Full-genome sequences of the first two SARS-CoV-2 viruses from India</article-title><source>Indian J Med Res</source><year>2020</year><volume>151</volume><issue>2 &#x00026; 3</issue><fpage>200</fpage><lpage>209</lpage><?supplied-pmid 32242873?><pub-id pub-id-type="pmid">32242873</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benvenuto</surname><given-names>D</given-names></name><name><surname>Giovanetti</surname><given-names>M</given-names></name><name><surname>Ciccozzi</surname><given-names>A</given-names></name><name><surname>Spoto</surname><given-names>S</given-names></name><name><surname>Angeletti</surname><given-names>S</given-names></name><name><surname>Ciccozzi</surname><given-names>M</given-names></name></person-group><article-title>The 2019-new coronavirus epidemic: evidence for virus evolution</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><issue>4</issue><fpage>455</fpage><lpage>459</lpage><?supplied-pmid 31994738?><pub-id pub-id-type="pmid">31994738</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maty&#x000e1;&#x00161;ek</surname><given-names>R</given-names></name><name><surname>Kova&#x00159;&#x000ed;k</surname><given-names>A</given-names></name></person-group><article-title>Mutation patterns of human SARS-CoV-2 and Bat RaTG13 coronavirus genomes are strongly biased towards C&#x02009;&#x0003e;&#x02009;U transitions, indicating rapid evolution in their hosts</article-title><source>Genes (Basel)</source><year>2020</year><volume>11</volume><issue>7</issue><fpage>E761</fpage><pub-id pub-id-type="pmid">32646049</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiwari</surname><given-names>M</given-names></name><name><surname>Mishra</surname><given-names>D</given-names></name></person-group><article-title>Investigating the genomic landscape of novel coronavirus (2019-nCoV) to identify non-synonymous mutations for use in diagnosis and drug design</article-title><source>J Clin Virol</source><year>2020</year><volume>128</volume><fpage>104441</fpage><?supplied-pmid 32425659?><pub-id pub-id-type="pmid">32425659</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>SS</given-names></name><name><surname>Choudhury</surname><given-names>PP</given-names></name><name><surname>Roy</surname><given-names>B</given-names></name></person-group><article-title>SARS-CoV2 envelope protein: non-synonymous mutations and its consequences</article-title><source>Genomics</source><year>2020</year><volume>112</volume><issue>6</issue><fpage>3890</fpage><lpage>3892</lpage></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>TJ</given-names></name><name><surname>Yang</surname><given-names>DM</given-names></name><name><surname>Wang</surname><given-names>ML</given-names></name><name><surname>Liang</surname><given-names>KH</given-names></name><name><surname>Tsai</surname><given-names>PH</given-names></name><name><surname>Chiou</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Genomic analysis and comparative multiple sequences of SARS-CoV2</article-title><source>J Chin Med Assoc</source><year>2020</year><volume>83</volume><issue>6</issue><fpage>537</fpage><lpage>543</lpage><?supplied-pmid 32349035?><pub-id pub-id-type="pmid">32349035</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begum</surname><given-names>F</given-names></name><name><surname>Mukherjee</surname><given-names>D</given-names></name><name><surname>Thagriki</surname><given-names>D</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Tripathi</surname><given-names>PP</given-names></name><name><surname>Banerjee</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Analyses of spike protein from first deposited sequences of SARS-CoV2 from West Bengal, India</article-title><source>F1000Research</source><year>2020</year><volume>9</volume><fpage>371</fpage><?supplied-pmid 32595958?><pub-id pub-id-type="pmid">32595958</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>SS</given-names></name><name><surname>Choudhury</surname><given-names>PP</given-names></name><name><surname>Basu</surname><given-names>P</given-names></name><name><surname>Jana</surname><given-names>SS</given-names></name></person-group><article-title>Molecular conservation and differential mutation on ORF3a gene in Indian SARS-CoV2 genomes</article-title><source>Genomics</source><year>2020</year><volume>112</volume><issue>5</issue><fpage>3226</fpage><lpage>3237</lpage><?supplied-pmid 32540495?><pub-id pub-id-type="pmid">32540495</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahmi</surname><given-names>M</given-names></name><name><surname>Kubota</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name></person-group><article-title>Nonstructural proteins NS7b and NS8 are likely to be phylogenetically associated with evolution of 2019-nCoV. 2586</article-title><source>Infect Genet Evol</source><year>2020</year><volume>81</volume><fpage>104272</fpage><?supplied-pmid 32142938?><pub-id pub-id-type="pmid">32142938</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Ye</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><etal/></person-group><article-title>RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak</article-title><source>Emerg Microbes Infect</source><year>2020</year><volume>9</volume><issue>1</issue><fpage>313</fpage><lpage>319</lpage><?supplied-pmid 32020836?><pub-id pub-id-type="pmid">32020836</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rokni</surname><given-names>M</given-names></name><name><surname>Ghasemi</surname><given-names>V</given-names></name><name><surname>Tavakoli</surname><given-names>Z</given-names></name></person-group><article-title>Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: comparison with SARS and MERS</article-title><source>Rev Med Virol</source><year>2020</year><volume>30</volume><issue>3</issue><fpage>e2107</fpage><?supplied-pmid 32267987?><pub-id pub-id-type="pmid">32267987</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavez</surname><given-names>S</given-names></name><name><surname>Long</surname><given-names>B</given-names></name><name><surname>Koyfman</surname><given-names>A</given-names></name><name><surname>Liang</surname><given-names>SY</given-names></name></person-group><article-title>Coronavirus Disease (COVID-19): a primer for emergency physicians</article-title><source>Am J Emerg Med</source><year>2020</year><volume>S0735&#x02013;6757</volume><issue>20</issue><fpage>30178</fpage><lpage>30179</lpage></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Clinical and immunologic features in severe and moderate coronavirus disease 2019</article-title><source>J Clin Invest</source><year>2020</year><volume>130</volume><issue>5</issue><fpage>2620</fpage><lpage>2629</lpage><?supplied-pmid 32217835?><pub-id pub-id-type="pmid">32217835</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lechien</surname><given-names>JR</given-names></name><name><surname>Chiesa-Estomba</surname><given-names>CM</given-names></name><name><surname>De Siati</surname><given-names>DR</given-names></name><name><surname>Horoi</surname><given-names>M</given-names></name><name><surname>Le Bon</surname><given-names>SD</given-names></name><name><surname>Rodriguez</surname><given-names>A</given-names></name><etal/></person-group><article-title>Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study</article-title><source>Eur Arch Otorhinolaryngol</source><year>2020</year><volume>277</volume><issue>8</issue><fpage>2251</fpage><lpage>2261</lpage><?supplied-pmid 32253535?><pub-id pub-id-type="pmid">32253535</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>SH</given-names></name><name><surname>Lui</surname><given-names>RN</given-names></name><name><surname>Sung</surname><given-names>JJ</given-names></name></person-group><article-title>Covid-19 and the digestive system</article-title><source>J Gastroenterol Hepatol</source><year>2020</year><volume>35</volume><issue>5</issue><fpage>744</fpage><lpage>748</lpage><pub-id pub-id-type="pmid">32215956</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>ED</given-names></name><name><surname>Fadda</surname><given-names>G</given-names></name><name><surname>Mule</surname><given-names>A</given-names></name><name><surname>Zannoni</surname><given-names>GF</given-names></name><name><surname>Rindi</surname><given-names>G</given-names></name></person-group><article-title>Cytologic and histologic samples from patients infected by the novel coronavirus 2019 SARS-CoV-2: an Italian institutional experience focusing on biosafety procedures</article-title><source>Cancer Cytopathol</source><year>2020</year><volume>128</volume><issue>5</issue><fpage>317</fpage><lpage>320</lpage><?supplied-pmid 32259373?><pub-id pub-id-type="pmid">32259373</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection</article-title><source>Gut</source><year>2020</year><volume>69</volume><issue>6</issue><fpage>997</fpage><lpage>1001</lpage><?supplied-pmid 32241899?><pub-id pub-id-type="pmid">32241899</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Tong</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>D</given-names></name></person-group><article-title>Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><issue>6</issue><fpage>589</fpage><lpage>594</lpage><?supplied-pmid 32100876?><pub-id pub-id-type="pmid">32100876</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>TM</given-names></name></person-group><article-title>Personal protective equipment during the COVID-19 pandemic&#x02014;a narrative review</article-title><source>Anaesthesia</source><year>2020</year><volume>75</volume><issue>7</issue><fpage>920</fpage><lpage>927</lpage><?supplied-pmid 32246849?><pub-id pub-id-type="pmid">32246849</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>YQ</given-names></name></person-group><article-title>From SARS to COVID-19: pathogens, receptor, pathogenesis and principles of the treatment</article-title><source>Zhonghua Bing Li Xue Za Zhi</source><year>2020</year><volume>49</volume><issue>6</issue><fpage>647</fpage><lpage>652</lpage><?supplied-pmid 32238232?><pub-id pub-id-type="pmid">32238232</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fantini</surname><given-names>J</given-names></name><name><surname>Scala</surname><given-names>CD</given-names></name><name><surname>Chahinian</surname><given-names>H</given-names></name><name><surname>Yahi</surname><given-names>N</given-names></name></person-group><article-title>Structural and molecular modeling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection</article-title><source>Int J Antimicrob Agents</source><year>2020</year><volume>55</volume><issue>5</issue><fpage>105960</fpage><?supplied-pmid 32251731?><pub-id pub-id-type="pmid">32251731</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>YB</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Zhou</surname><given-names>ZJ</given-names></name><name><surname>Liao</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2</article-title><source>Microbes Infect</source><year>2020</year><volume>22</volume><issue>4&#x02013;5</issue><fpage>221</fpage><lpage>225</lpage><?supplied-pmid 32199943?><pub-id pub-id-type="pmid">32199943</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>South</surname><given-names>AM</given-names></name><name><surname>Tomlinson</surname><given-names>L</given-names></name><name><surname>Edmonston</surname><given-names>D</given-names></name><name><surname>Hiremath</surname><given-names>S</given-names></name><name><surname>Sparks</surname><given-names>MA</given-names></name></person-group><article-title>Controversies of renin&#x02013;angiotensin system inhibition during the COVID-19 pandemic</article-title><source>Nat Rev Nephrol</source><year>2020</year><volume>16</volume><issue>6</issue><fpage>305</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">32246101</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Xi</surname><given-names>J</given-names></name></person-group><article-title>CD-sACE2 inclusion compounds: an effective treatment for corona virus disease 2019 (COVID-19)</article-title><source>J Med Virol</source><year>2020</year><pub-id pub-id-type="doi">10.1002/jmv.25804</pub-id><?supplied-pmid 32880993?><pub-id pub-id-type="pmid">32880993</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>South</surname><given-names>AM</given-names></name><name><surname>Diz</surname><given-names>D</given-names></name><name><surname>Chappell</surname><given-names>MC</given-names></name></person-group><article-title>COVID-19, ACE2 and the cardiovascular consequences</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2020</year><volume>318</volume><issue>5</issue><fpage>H1084</fpage><lpage>H1090</lpage><?supplied-pmid 32228252?><pub-id pub-id-type="pmid">32228252</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N</given-names></name><name><surname>Herrler</surname><given-names>T</given-names></name><name><surname>Erichsen</surname><given-names>S</given-names></name><etal/></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><year>2020</year><volume>181</volume><issue>2</issue><fpage>271</fpage><lpage>280</lpage><?supplied-pmid 32142651?><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasi</surname><given-names>A</given-names></name><name><surname>McArdle</surname><given-names>S</given-names></name><name><surname>Gaudernack</surname><given-names>G</given-names></name><name><surname>Westman</surname><given-names>G</given-names></name><name><surname>Melief</surname><given-names>C</given-names></name><name><surname>Rockberg</surname><given-names>J</given-names></name><etal/></person-group><article-title>Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention. Version 2</article-title><source>Toxicol Rep</source><year>2020</year><volume>7</volume><fpage>768</fpage><lpage>771</lpage><?supplied-pmid 32632359?><pub-id pub-id-type="pmid">32632359</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>A</given-names></name><etal/></person-group><article-title>Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients</article-title><source>Emerg Microbes Infect</source><year>2020</year><volume>9</volume><issue>1</issue><fpage>761</fpage><lpage>770</lpage><?supplied-pmid 32228226?><pub-id pub-id-type="pmid">32228226</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Duan</surname><given-names>J</given-names></name><name><surname>Hashimoto</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Nervous system involvement after infection with COVID-19 and other coronaviruses</article-title><source>Brain Behav Immun</source><year>2020</year><volume>87</volume><fpage>18</fpage><lpage>22</lpage><?supplied-pmid 32240762?><pub-id pub-id-type="pmid">32240762</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>HL</given-names></name><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Matalon</surname><given-names>S</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name></person-group><article-title>Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility</article-title><source>Physiol Rev</source><year>2020</year><volume>100</volume><issue>3</issue><fpage>1065</fpage><lpage>1075</lpage><?supplied-pmid 32216698?><pub-id pub-id-type="pmid">32216698</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahid</surname><given-names>Z</given-names></name><name><surname>Kalayanamitra</surname><given-names>R</given-names></name><name><surname>McClafferty</surname><given-names>B</given-names></name><name><surname>Kepko</surname><given-names>D</given-names></name><name><surname>Ramgobin</surname><given-names>D</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><etal/></person-group><article-title>COVID-19 and older adults: what we know</article-title><source>J Am Geriatr Soc</source><year>2020</year><volume>68</volume><issue>5</issue><fpage>926</fpage><lpage>929</lpage><?supplied-pmid 32255507?><pub-id pub-id-type="pmid">32255507</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Possible causes for decreased susceptibility of children to coronavirus</article-title><source>Pediatr Res</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41390-020-0892-8</pub-id><?supplied-pmid 32438368?><pub-id pub-id-type="pmid">32438368</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhochak</surname><given-names>N</given-names></name><name><surname>Singhal</surname><given-names>T</given-names></name><name><surname>Kabra</surname><given-names>SK</given-names></name><name><surname>Lodha</surname><given-names>R</given-names></name></person-group><article-title>Pathophysiology of COVID-19: why children fare better than adults?</article-title><source>Indian J Pediatr</source><year>2020</year><volume>87</volume><issue>7</issue><fpage>537</fpage><lpage>546</lpage><?supplied-pmid 32410003?><pub-id pub-id-type="pmid">32410003</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conti</surname><given-names>P</given-names></name><name><surname>Younes</surname><given-names>A</given-names></name></person-group><article-title>Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection</article-title><source>J Biol Regul Homeost Agents</source><year>2020</year><pub-id pub-id-type="doi">10.23812/editorial-conti-3</pub-id><?supplied-pmid 32945158?><pub-id pub-id-type="pmid">32945158</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babapoor-Farrokhran</surname><given-names>S</given-names></name><name><surname>Gill</surname><given-names>D</given-names></name><name><surname>Walker</surname><given-names>J</given-names></name><name><surname>Rasekhi</surname><given-names>RT</given-names></name><name><surname>Bozorgnia</surname><given-names>B</given-names></name><name><surname>Amanullah</surname><given-names>A</given-names></name></person-group><article-title>Myocardial injury and COVID-19: possible mechanisms</article-title><source>Life Sci</source><year>2020</year><volume>253</volume><fpage>117723</fpage><?supplied-pmid 32360126?><pub-id pub-id-type="pmid">32360126</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuschieri</surname><given-names>S</given-names></name><name><surname>Grech</surname><given-names>S</given-names></name></person-group><article-title>COVID-19 and diabetes: the why, the what and the how</article-title><source>J Diabetes Complicat</source><year>2020</year><volume>22</volume><fpage>107637</fpage><pub-id pub-id-type="doi">10.1016/j.jdiacomp.2020.107637</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>L</given-names></name><name><surname>Dutta</surname><given-names>P</given-names></name></person-group><article-title>SGLT2 inhibition and COVID-19: the road not taken</article-title><source>Eur J Clin Invest</source><year>2020</year><volume>10</volume><fpage>e13339</fpage><pub-id pub-id-type="doi">10.1111/eci.13339</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasanagic</surname><given-names>S</given-names></name><name><surname>Serdarevic</surname><given-names>F</given-names></name></person-group><article-title>Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors (nAChR) and beyond</article-title><source>Eur Respir J</source><year>2020</year><volume>18</volume><fpage>2001610</fpage><pub-id pub-id-type="doi">10.1183/13993003.01610-2020</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name></person-group><article-title>Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis</article-title><source>Aging (Albany NY)</source><year>2020</year><volume>12</volume><issue>7</issue><fpage>6049</fpage><lpage>6057</lpage><pub-id pub-id-type="pmid">32267833</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Zuo</surname><given-names>Z</given-names></name><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Cai</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019</article-title><source>Int J Infect Dis</source><year>2020</year><volume>94</volume><fpage>49</fpage><lpage>52</lpage><?supplied-pmid 32251798?><pub-id pub-id-type="pmid">32251798</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name></person-group><article-title>Detection of antibodies against SARS-CoV-2 in patients with COVID-19</article-title><source>J Med Virol</source><year>2020</year><pub-id pub-id-type="doi">10.1002/jmv.25820</pub-id><?supplied-pmid 32869863?><pub-id pub-id-type="pmid">32869863</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Yi</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Xiong</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><etal/></person-group><article-title>Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis</article-title><source>J Med Virol</source><year>2020</year><pub-id pub-id-type="doi">10.1002/jmv.25727</pub-id><?supplied-pmid 32936465?><pub-id pub-id-type="pmid">32936465</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>L</given-names></name></person-group><article-title>CT features of coronavirus disease 2019 (COVID-19) pneumonia in 62 patients in Wuhan, China</article-title><source>AJR Am J Roentgenol</source><year>2020</year><volume>214</volume><issue>6</issue><fpage>1287</fpage><lpage>1294</lpage><?supplied-pmid 32134681?><pub-id pub-id-type="pmid">32134681</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Deng</surname><given-names>R</given-names></name><name><surname>Gou</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Shao</surname><given-names>F</given-names></name><etal/></person-group><article-title>Preliminary study to identify severe from moderate cases of COVID-19 using combined hematology parameters</article-title><source>Ann Transl Med</source><year>2020</year><volume>8</volume><issue>9</issue><fpage>593</fpage><?supplied-pmid 32566620?><pub-id pub-id-type="pmid">32566620</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>M</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name></person-group><article-title>A case report of COVID-19 with false negative RT-PCR test: necessity of chest CT</article-title><source>Jpn J Radiol</source><year>2020</year><volume>38</volume><issue>5</issue><fpage>409</fpage><lpage>410</lpage><?supplied-pmid 32266524?><pub-id pub-id-type="pmid">32266524</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolters</surname><given-names>F</given-names></name><name><surname>van de Bovenkamp</surname><given-names>J</given-names></name><name><surname>van den Bosch</surname><given-names>B</given-names></name><name><surname>van den Brink</surname><given-names>S</given-names></name><name><surname>Broeders</surname><given-names>M</given-names></name><name><surname>Chung</surname><given-names>NH</given-names></name><etal/></person-group><article-title>Multi-center evaluation of cepheid xpert<sup>&#x000ae;</sup> xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic</article-title><source>J Clin Virol</source><year>2020</year><volume>128</volume><fpage>104426</fpage><?supplied-pmid 32417674?><pub-id pub-id-type="pmid">32417674</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>P</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Long</surname><given-names>J</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>The epidemiology, diagnosis and treatment of COVID-19</article-title><source>Int J Antimicrob Agents</source><year>2020</year><volume>55</volume><issue>5</issue><fpage>105955</fpage><?supplied-pmid 32234468?><pub-id pub-id-type="pmid">32234468</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dworza&#x00144;ska</surname><given-names>A</given-names></name><name><surname>Tudrujek-Zdunek</surname><given-names>M</given-names></name><name><surname>Mosiewicz</surname><given-names>J</given-names></name><name><surname>Panasiuk</surname><given-names>L</given-names></name><name><surname>Tomasiewicz</surname><given-names>K</given-names></name></person-group><article-title>A 56-year-old man with RT-PCR negative nasopharyngeal swabs with Coronavirus Disease 2019 (COVID-19) Pneumonia</article-title><source>Ann Agric Environ Med</source><year>2020</year><volume>27</volume><issue>2</issue><fpage>317</fpage><lpage>318</lpage><?supplied-pmid 32588614?><pub-id pub-id-type="pmid">32588614</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thabet</surname><given-names>L</given-names></name><name><surname>Mhalla</surname><given-names>S</given-names></name><name><surname>Naija</surname><given-names>H</given-names></name><name><surname>Jaoua</surname><given-names>MA</given-names></name><name><surname>Hannachi</surname><given-names>N</given-names></name><name><surname>Fki-Berrajah</surname><given-names>L</given-names></name><name><surname>Toumi</surname><given-names>A</given-names></name><name><surname>Karray-Hakim</surname><given-names>H</given-names></name></person-group><article-title>SARS-CoV-2 infection virological diagnosis</article-title><source>Tunis Med</source><year>2020</year><volume>98</volume><issue>4</issue><fpage>304</fpage><lpage>308</lpage><?supplied-pmid 32395793?><pub-id pub-id-type="pmid">32395793</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>J&#x00119;drusik</surname><given-names>P</given-names></name><name><surname>Gaciong</surname><given-names>Z</given-names></name><name><surname>Sklinda</surname><given-names>K</given-names></name><name><surname>Sierpi&#x00144;ski</surname><given-names>R</given-names></name><name><surname>Walecki</surname><given-names>J</given-names></name><name><surname>Gujski</surname><given-names>M</given-names></name></person-group><article-title>Diagnostic role of chest computed tomography in coronavirus disease 2019</article-title><source>Pol Arch Intern Med</source><year>2020</year><volume>130</volume><issue>6</issue><fpage>520</fpage><lpage>528</lpage><?supplied-pmid 32385976?><pub-id pub-id-type="pmid">32385976</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salehi</surname><given-names>S</given-names></name><name><surname>Abedi</surname><given-names>A</given-names></name><name><surname>Balakrishnan</surname><given-names>S</given-names></name><name><surname>Gholamrezanezhad</surname><given-names>A</given-names></name></person-group><article-title>Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients</article-title><source>AJR Am J Roentgenol</source><year>2020</year><volume>215</volume><issue>1</issue><fpage>87</fpage><lpage>93</lpage><?supplied-pmid 32174129?><pub-id pub-id-type="pmid">32174129</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zeng</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>CT imaging changes of corona virus disease 2019 (COVID-19): a multi-center study in Southwest China</article-title><source>J Transl Med</source><year>2020</year><volume>18</volume><issue>1</issue><fpage>154</fpage><?supplied-pmid 32252784?><pub-id pub-id-type="pmid">32252784</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobi</surname><given-names>A</given-names></name><name><surname>Chung</surname><given-names>M</given-names></name><name><surname>Bernheim</surname><given-names>A</given-names></name><name><surname>Eber</surname><given-names>C</given-names></name></person-group><article-title>Portable chest X-ray in coronavirus disease-19 (COVID-19): a pictorial review</article-title><source>Clin Imaging</source><year>2020</year><volume>64</volume><fpage>35</fpage><lpage>42</lpage><?supplied-pmid 32302927?><pub-id pub-id-type="pmid">32302927</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cozzi</surname><given-names>D</given-names></name><name><surname>Albanesi</surname><given-names>M</given-names></name><name><surname>Cavigli</surname><given-names>E</given-names></name><name><surname>Moroni</surname><given-names>C</given-names></name><name><surname>Bindi</surname><given-names>A</given-names></name><name><surname>Luvar&#x000e0;</surname><given-names>S</given-names></name><etal/></person-group><article-title>Chest X-ray in new Coronavirus Disease 2019 (COVID-19) infection: findings and correlation with clinical outcome</article-title><source>Radiol Med</source><year>2020</year><volume>125</volume><issue>8</issue><fpage>730</fpage><lpage>737</lpage><?supplied-pmid 32519256?><pub-id pub-id-type="pmid">32519256</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>SF</given-names></name><name><surname>Ho</surname><given-names>YC</given-names></name></person-group><article-title>SARS-CoV-2: a storm is raging</article-title><source>J Clin Invest</source><year>2020</year><volume>130</volume><issue>5</issue><fpage>2202</fpage><lpage>2205</lpage><?supplied-pmid 32217834?><pub-id pub-id-type="pmid">32217834</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Hajizadeh</surname><given-names>N</given-names></name><name><surname>Moore</surname><given-names>EE</given-names></name><name><surname>McIntyre</surname><given-names>RC</given-names></name><name><surname>Moore</surname><given-names>PK</given-names></name><name><surname>Veress</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series</article-title><source>J Thromb Haemost</source><year>2020</year><volume>18</volume><issue>7</issue><fpage>1752</fpage><lpage>1755</lpage><?supplied-pmid 32267998?><pub-id pub-id-type="pmid">32267998</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>SC</given-names></name><name><surname>Kwong</surname><given-names>RT</given-names></name><name><surname>Wu</surname><given-names>TC</given-names></name><name><surname>Chan</surname><given-names>JWM</given-names></name><name><surname>Chu</surname><given-names>MY</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Risk of nosocomial transmission of coronavirus disease 2019: an experience in a general ward setting in Hong Kong</article-title><source>J Hosp Infect</source><year>2020</year><volume>105</volume><issue>2</issue><fpage>119</fpage><lpage>127</lpage><?supplied-pmid 32259546?><pub-id pub-id-type="pmid">32259546</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Usher</surname><given-names>K</given-names></name><name><surname>Bhullar</surname><given-names>N</given-names></name><name><surname>Jackson</surname><given-names>D</given-names></name></person-group><article-title>Life in the pandemic: social isolation and mental health</article-title><source>J Clin Nurs</source><year>2020</year><pub-id pub-id-type="doi">10.1111/jocn.15290</pub-id><?supplied-pmid 32896006?><pub-id pub-id-type="pmid">32896006</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>X</given-names></name><name><surname>Xiong</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name></person-group><article-title>Extracorporeal membrane oxygenation (ECMO): does it have a role in the treatment of severe COVID-19?</article-title><source>Int J Infect Dis</source><year>2020</year><volume>94</volume><fpage>78</fpage><lpage>80</lpage><?supplied-pmid 32251794?><pub-id pub-id-type="pmid">32251794</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sodhi</surname><given-names>M</given-names></name><name><surname>Etminan</surname><given-names>M</given-names></name></person-group><article-title>Therapeutic potential for tetracyclines in the treatment of COVID-19</article-title><source>Pharmacotherapy</source><year>2020</year><volume>40</volume><issue>5</issue><fpage>487</fpage><lpage>488</lpage><?supplied-pmid 32267566?><pub-id pub-id-type="pmid">32267566</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caly</surname><given-names>L</given-names></name><name><surname>Druce</surname><given-names>JD</given-names></name><name><surname>Catton</surname><given-names>MG</given-names></name><name><surname>Jans</surname><given-names>DA</given-names></name><name><surname>Wagstaff</surname><given-names>KM</given-names></name></person-group><article-title>The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro</article-title><source>Antivir Res</source><year>2020</year><volume>178</volume><fpage>104787</fpage><?supplied-pmid 32251768?><pub-id pub-id-type="pmid">32251768</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Tai</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Geng</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Molecular mechanism for antibody-dependent enhancement of coronavirus entry</article-title><source>J Virol</source><year>2020</year><volume>94</volume><issue>5</issue><fpage>e02015</fpage><lpage>e02019</lpage><?supplied-pmid 31826992?><pub-id pub-id-type="pmid">31826992</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Jiagao</surname><given-names>Lv J</given-names></name></person-group><article-title>Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection</article-title><source>J Am Heart Assoc</source><year>2020</year><volume>9</volume><issue>7</issue><fpage>e016219</fpage><?supplied-pmid 32233755?><pub-id pub-id-type="pmid">32233755</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danser</surname><given-names>AHJ</given-names></name><name><surname>Epstein</surname><given-names>M</given-names></name><name><surname>Batlle</surname><given-names>D</given-names></name></person-group><article-title>Renin-Angiotensin System blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers</article-title><source>Hypertension</source><year>2020</year><volume>75</volume><issue>6</issue><fpage>1382</fpage><lpage>1385</lpage><?supplied-pmid 32208987?><pub-id pub-id-type="pmid">32208987</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohe</surname><given-names>M</given-names></name><name><surname>Shida</surname><given-names>H</given-names></name><name><surname>Jodo</surname><given-names>S</given-names></name><name><surname>Kusunoki</surname><given-names>Y</given-names></name><name><surname>Seki</surname><given-names>M</given-names></name><name><surname>Furuya</surname><given-names>K</given-names></name><etal/></person-group><article-title>Macrolide treatment for COVID-19: will this be the way forward?</article-title><source>Biosci Trends</source><year>2020</year><volume>14</volume><issue>2</issue><fpage>159</fpage><lpage>160</lpage><?supplied-pmid 32249257?><pub-id pub-id-type="pmid">32249257</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>MK</given-names></name><name><surname>Vemula</surname><given-names>S</given-names></name><name><surname>Donde</surname><given-names>R</given-names></name><name><surname>Gouda</surname><given-names>G</given-names></name><name><surname>Behera</surname><given-names>L</given-names></name><name><surname>Vadde</surname><given-names>R</given-names></name></person-group><article-title>In silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel</article-title><source>J Biomol Struct Dyn</source><year>2020</year><volume>15</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1751300</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>R</given-names></name><name><surname>Chakraborty</surname><given-names>A</given-names></name><name><surname>Biswas</surname><given-names>A</given-names></name><name><surname>Chowdhuri</surname><given-names>S</given-names></name></person-group><article-title>Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors&#x02014;an in silico docking and molecular dynamics simulation study</article-title><source>J Biomol Struct Dyn</source><year>2020</year><volume>22</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1779818</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Kushwaha</surname><given-names>PP</given-names></name><name><surname>Prajapati</surname><given-names>KS</given-names></name><name><surname>Shuaib</surname><given-names>M</given-names></name><name><surname>Senapati</surname><given-names>S</given-names></name><etal/></person-group><article-title>Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies</article-title><source>J Biomol Struct Dyn</source><year>2020</year><volume>11</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1776157</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortega</surname><given-names>JT</given-names></name><name><surname>Serrano</surname><given-names>ML</given-names></name><name><surname>Jastrzebska</surname><given-names>B</given-names></name></person-group><article-title>Class A G protein-coupled receptor antagonist famotidine as a therapeutic alternative against SARS-CoV2: an in silico analysis</article-title><source>Biomolecules</source><year>2020</year><volume>10</volume><issue>6</issue><fpage>954</fpage></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devaux</surname><given-names>CA</given-names></name><name><surname>Rolain</surname><given-names>JM</given-names></name><name><surname>Colson</surname><given-names>P</given-names></name><name><surname>Raoult</surname><given-names>D</given-names></name></person-group><article-title>New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?</article-title><source>Int J Antimicrob Agents</source><year>2020</year><volume>55</volume><issue>5</issue><fpage>105938</fpage><?supplied-pmid 32171740?><pub-id pub-id-type="pmid">32171740</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro</article-title><source>Cell Discov</source><year>2020</year><volume>6</volume><fpage>16</fpage><?supplied-pmid 32194981?><pub-id pub-id-type="pmid">32194981</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Dai</surname><given-names>SM</given-names></name><name><surname>Tong</surname><given-names>Q</given-names></name></person-group><article-title>COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression</article-title><source>J Antimicrob Chemother</source><year>2020</year><volume>75</volume><issue>7</issue><fpage>1667</fpage><lpage>1670</lpage><?supplied-pmid 32196083?><pub-id pub-id-type="pmid">32196083</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautret</surname><given-names>P</given-names></name><name><surname>Lagier</surname><given-names>JC</given-names></name><name><surname>Parola</surname><given-names>P</given-names></name><name><surname>Hoang</surname><given-names>VT</given-names></name><name><surname>Meddeb</surname><given-names>L</given-names></name><name><surname>Mailhe</surname><given-names>M</given-names></name><etal/></person-group><article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</article-title><source>Int J Antimicrob Agents</source><year>2020</year><volume>56</volume><issue>1</issue><fpage>105949</fpage><?supplied-pmid 32205204?><pub-id pub-id-type="pmid">32205204</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>YX</given-names></name><name><surname>Chen</surname><given-names>XP</given-names></name></person-group><article-title>Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection</article-title><source>Clin Pharmacol Ther</source><year>2020</year><volume>108</volume><issue>2</issue><fpage>242</fpage><lpage>247</lpage><?supplied-pmid 32246834?><pub-id pub-id-type="pmid">32246834</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reina</surname><given-names>J</given-names></name></person-group><article-title>Remdesivir, the antiviral hope against SARS-CoV-2</article-title><source>Rev Esp Quimioter</source><year>2020</year><volume>33</volume><issue>3</issue><fpage>176</fpage><lpage>179</lpage><?supplied-pmid 32239125?><pub-id pub-id-type="pmid">32239125</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>CJ</given-names></name><name><surname>Tchesnokov</surname><given-names>EP</given-names></name><name><surname>Feng</surname><given-names>JY</given-names></name><name><surname>Porter</surname><given-names>DP</given-names></name><name><surname>Gotte</surname><given-names>M</given-names></name></person-group><article-title>The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus</article-title><source>J Biol Chem</source><year>2020</year><volume>295</volume><issue>15</issue><fpage>4773</fpage><lpage>4779</lpage><?supplied-pmid 32094225?><pub-id pub-id-type="pmid">32094225</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muralidharan</surname><given-names>N</given-names></name><name><surname>Sakthivel</surname><given-names>R</given-names></name><name><surname>Velmurugan</surname><given-names>D</given-names></name><name><surname>Gromiha</surname><given-names>MM</given-names></name></person-group><article-title>Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 Protease against COVID-19</article-title><source>J Biomol Struct Dyn</source><year>2020</year><volume>16</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1752802</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srinivas</surname><given-names>P</given-names></name><name><surname>Sacha</surname><given-names>G</given-names></name><name><surname>Koval</surname><given-names>C</given-names></name></person-group><article-title>Antivirals for COVID-19</article-title><source>Cleve Clin J Med</source><year>2020</year><pub-id pub-id-type="doi">10.3949/ccjm.87a.ccc030</pub-id><?supplied-pmid 32409433?><pub-id pub-id-type="pmid">32409433</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leng</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>R</given-names></name><name><surname>Hou</surname><given-names>W</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia</article-title><source>Aging Dis</source><year>2020</year><volume>11</volume><issue>2</issue><fpage>216</fpage><lpage>228</lpage><?supplied-pmid 32257537?><pub-id pub-id-type="pmid">32257537</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam Monteagudo</surname><given-names>L</given-names></name><name><surname>Boothby</surname><given-names>A</given-names></name><name><surname>Gertner</surname><given-names>E</given-names></name></person-group><article-title>Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome</article-title><source>ACR Open Rheumatol</source><year>2020</year><volume>2</volume><issue>5</issue><fpage>276</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">32267081</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>JW</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>GQ</given-names></name></person-group><article-title>The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality</article-title><source>Int J Antimicrob Agents</source><year>2020</year><volume>55</volume><issue>5</issue><fpage>105954</fpage><?supplied-pmid 32234467?><pub-id pub-id-type="pmid">32234467</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diurno</surname><given-names>F</given-names></name><name><surname>Numis</surname><given-names>FG</given-names></name><name><surname>Porta</surname><given-names>G</given-names></name><name><surname>Cirillo</surname><given-names>F</given-names></name><name><surname>Maddaluno</surname><given-names>S</given-names></name><name><surname>Ragozzino</surname><given-names>A</given-names></name><etal/></person-group><article-title>Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2020</year><volume>24</volume><issue>7</issue><fpage>4040</fpage><lpage>4047</lpage><?supplied-pmid 32329881?><pub-id pub-id-type="pmid">32329881</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saghazadeh</surname><given-names>A</given-names></name><name><surname>Rezaei</surname><given-names>N</given-names></name></person-group><article-title>Towards treatment planning of COVID-19: rationale and hypothesis for the use of multiple immunosuppressive agents: anti-antibodies, immunoglobulins, and corticosteroids</article-title><source>Int Immunopharmacol</source><year>2020</year><volume>84</volume><fpage>106560</fpage><?supplied-pmid 32413736?><pub-id pub-id-type="pmid">32413736</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>B</given-names></name><name><surname>Moss</surname><given-names>C</given-names></name><name><surname>Rigg</surname><given-names>A</given-names></name><name><surname>Van Hemelrijck</surname><given-names>M</given-names></name></person-group><article-title>COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?</article-title><source>Ecancermedicalscience</source><year>2020</year><volume>14</volume><fpage>1023</fpage><?supplied-pmid 32256706?><pub-id pub-id-type="pmid">32256706</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>PM</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Sanchez</surname><given-names>E</given-names></name><name><surname>Tattersall</surname><given-names>RS</given-names></name><name><surname>Manson</surname><given-names>JJ</given-names></name></person-group><article-title>COVID-19: consider cytokine storm syndromes and immunosuppression</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10229</issue><fpage>1033</fpage><lpage>1034</lpage><?supplied-pmid 32192578?><pub-id pub-id-type="pmid">32192578</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Runfeng</surname><given-names>L</given-names></name><name><surname>Yunlong</surname><given-names>H</given-names></name><name><surname>Jicheng</surname><given-names>H</given-names></name><name><surname>Weiqi</surname><given-names>P</given-names></name><name><surname>Qinhai</surname><given-names>M</given-names></name><name><surname>Yongxia</surname><given-names>S</given-names></name><etal/></person-group><article-title>Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)</article-title><source>Pharmacol Res</source><year>2020</year><volume>156</volume><fpage>104761</fpage><?supplied-pmid 32205232?><pub-id pub-id-type="pmid">32205232</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maideen</surname><given-names>NMP</given-names></name></person-group><article-title>Prophetic medicine-Nigella Sativa (Black cumin seeds)&#x02014;potential herb for COVID-19?</article-title><source>J Pharmacopunct</source><year>2020</year><volume>23</volume><issue>2</issue><fpage>62</fpage><lpage>70</lpage></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>Y</given-names></name><name><surname>Gupta</surname><given-names>G</given-names></name><name><surname>Kazmi</surname><given-names>I</given-names></name><name><surname>Al-Abbasi</surname><given-names>FA</given-names></name><name><surname>Negi</surname><given-names>P</given-names></name><name><surname>Chellappan</surname><given-names>DK</given-names></name><etal/></person-group><article-title>SARS CoV-2 aggravates cellular metabolism mediated complications in COVID-19 infection</article-title><source>Dermatol Ther</source><year>2020</year><volume>18</volume><fpage>e13871</fpage><pub-id pub-id-type="doi">10.1111/dth.13871</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloch</surname><given-names>EM</given-names></name><name><surname>Shoham</surname><given-names>S</given-names></name><name><surname>Casadevall</surname><given-names>A</given-names></name><name><surname>Sachais</surname><given-names>BS</given-names></name><name><surname>Shaz</surname><given-names>B</given-names></name><name><surname>Winters</surname><given-names>JL</given-names></name><name><surname>Tobian</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Deployment of convalescent plasma for the prevention and treatment of COVID-19</article-title><source>J Clin Invest</source><year>2020</year><volume>130</volume><issue>6</issue><fpage>2757</fpage><lpage>2765</lpage><?supplied-pmid 32254064?><pub-id pub-id-type="pmid">32254064</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effectiveness of convalescent plasma therapy in severe COVID-19 patients</article-title><source>Proc Natl Acad Sci USA</source><year>2020</year><volume>117</volume><issue>17</issue><fpage>9490</fpage><lpage>9496</lpage><?supplied-pmid 32253318?><pub-id pub-id-type="pmid">32253318</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><etal/></person-group><article-title>Treatment of 5 critically ill patients with COVID-19 with convalescent plasma</article-title><source>JAMA</source><year>2020</year><volume>323</volume><issue>16</issue><fpage>1582</fpage><lpage>1589</lpage><?supplied-pmid 32219428?><pub-id pub-id-type="pmid">32219428</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>YW</given-names></name><name><surname>Schmitz</surname><given-names>JE</given-names></name><name><surname>Persing</surname><given-names>DH</given-names></name><name><surname>Stratton</surname><given-names>CW</given-names></name></person-group><article-title>The laboratory diagnosis of COVID-19 infection: current issues and challenges</article-title><source>J Clin Microbiol</source><year>2020</year><volume>58</volume><issue>6</issue><fpage>e00512</fpage><lpage>e00520</lpage><?supplied-pmid 32245835?><pub-id pub-id-type="pmid">32245835</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YZ</given-names></name><name><surname>Holmes</surname><given-names>EC</given-names></name></person-group><article-title>A genomic perspective on the origin and emergence of SARS-CoV-2</article-title><source>Cell</source><year>2020</year><volume>181</volume><issue>2</issue><fpage>223</fpage><lpage>227</lpage><?supplied-pmid 32220310?><pub-id pub-id-type="pmid">32220310</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grubaugh</surname><given-names>ND</given-names></name><name><surname>Petrone</surname><given-names>ME</given-names></name><name><surname>Holmes</surname><given-names>EC</given-names></name></person-group><article-title>We shouldn&#x02019;t worry when a virus mutates during disease outbreaks</article-title><source>Nat Microbiol</source><year>2020</year><volume>5</volume><issue>4</issue><fpage>529</fpage><lpage>530</lpage><?supplied-pmid 32071422?><pub-id pub-id-type="pmid">32071422</pub-id></element-citation></ref></ref-list></back></article>